The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.

Harder H, Nielsen L, Tu DT, Astrup A

Diabetes care1 Aug 2004Cited by 176 (Europe PMC)

PMID15277417DOI10.2337/diacare.27.8.1915PepBankPUB-15277417

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In obese adults with type 2 diabetes, liraglutide 0.6 mg reduced fasting serum glucose compared with placebo after 8 weeks.
In plain wordsIn obese adults with type 2 diabetes, liraglutide lowered fasting blood sugar more than placebo.
Peptide
Liraglutide
Outcome
DecreaseFasting serum glucose
Study
n = 33
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg once daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
After 8 weeks, liraglutide reduced fasting serum glucose (liraglutide, -1.90 mmol/l, and placebo, 0.27 mmol/l; P = 0.002)
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-three patients (mean +/- SD) aged 60.0 +/- 9.5 years, with HbA(1c) 7.5 +/- 1.2% and BMI 36.6 +/- 4.1 kg/m(2), were randomized to treatment with a single daily subcutaneous dose of 0.6 mg liraglutide (n = 21) or placebo (n = 12) for 8 weeks.
Report a problemFND-1527741701
02HumanRandomized controlled trialEfficacy outcome
In obese adults with type 2 diabetes, liraglutide 0.6 mg reduced HbA1c compared with placebo after 8 weeks.
In plain wordsIn obese adults with type 2 diabetes, liraglutide lowered HbA1c more than placebo.
Peptide
Liraglutide
Outcome
DecreaseHbA1c
Study
n = 33
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg once daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
and HbA(1c) (liraglutide, -0.33%, and placebo, 0.47%; P = 0.028) compared with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-three patients (mean +/- SD) aged 60.0 +/- 9.5 years, with HbA(1c) 7.5 +/- 1.2% and BMI 36.6 +/- 4.1 kg/m(2), were randomized to treatment with a single daily subcutaneous dose of 0.6 mg liraglutide (n = 21) or placebo (n = 12) for 8 weeks.
Report a problemFND-1527741702
03HumanRandomized controlled trialEfficacy outcome
In obese adults with type 2 diabetes, no change in body weight was detected with liraglutide 0.6 mg compared with placebo.
In plain wordsIn obese adults with type 2 diabetes, liraglutide did not change body weight compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeBody weight
Study
n = 33
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
0.6 mg once daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
No change in body weight was detected (liraglutide, -0.7 kg, and placebo, -0.9 kg; P = 0.756).
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-three patients (mean +/- SD) aged 60.0 +/- 9.5 years, with HbA(1c) 7.5 +/- 1.2% and BMI 36.6 +/- 4.1 kg/m(2), were randomized to treatment with a single daily subcutaneous dose of 0.6 mg liraglutide (n = 21) or placebo (n = 12) for 8 weeks.
Report a problemFND-1527741703
04HumanRandomized controlled trialEfficacy outcome
In obese adults with type 2 diabetes, liraglutide showed only a nonsignificant trend toward lower total fat mass compared with placebo.
In plain wordsIn obese adults with type 2 diabetes, fat mass tended to fall with liraglutide, but the difference from placebo was not significant.
Peptide
Liraglutide
Outcome
No significant changeTotal fat mass
Study
n = 33
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
0.6 mg once daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
There was a nonsignificant trend toward a decrease in total fat mass (liraglutide, -0.98%, and placebo, -0.12%; P = 0.088)
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-three patients (mean +/- SD) aged 60.0 +/- 9.5 years, with HbA(1c) 7.5 +/- 1.2% and BMI 36.6 +/- 4.1 kg/m(2), were randomized to treatment with a single daily subcutaneous dose of 0.6 mg liraglutide (n = 21) or placebo (n = 12) for 8 weeks.
Report a problemFND-1527741704
05HumanRandomized controlled trialEfficacy outcome
In obese adults with type 2 diabetes, liraglutide showed only a nonsignificant trend toward higher lean body mass compared with placebo.
In plain wordsIn obese adults with type 2 diabetes, lean mass tended to rise with liraglutide, but the difference from placebo was not significant.
Peptide
Liraglutide
Outcome
No significant changeLean body mass
Study
n = 33
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
0.6 mg once daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
and toward an increase in lean body mass (liraglutide, 1.02%, and placebo, 0.23%; P = 0.118) in the liraglutide group compared with the placebo group.
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-three patients (mean +/- SD) aged 60.0 +/- 9.5 years, with HbA(1c) 7.5 +/- 1.2% and BMI 36.6 +/- 4.1 kg/m(2), were randomized to treatment with a single daily subcutaneous dose of 0.6 mg liraglutide (n = 21) or placebo (n = 12) for 8 weeks.
Report a problemFND-1527741705
06HumanRandomized controlled trialEfficacy outcome
In obese adults with type 2 diabetes, 24-h energy expenditure was unaffected by liraglutide 0.6 mg compared with placebo.
In plain wordsIn obese adults with type 2 diabetes, liraglutide did not change 24-hour energy use compared with placebo.
Peptide
Liraglutide
Outcome
No significant change24-h energy expenditure
Study
n = 33
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
0.6 mg once daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
Twenty-four-hour energy expenditure was unaffected by the treatment (liraglutide, -12.6 kJ/h, and placebo, -13.7 kJ/h; P = 0.799).
1 context sentence(design, population, supporting numbers)
Summary · context
Thirty-three patients (mean +/- SD) aged 60.0 +/- 9.5 years, with HbA(1c) 7.5 +/- 1.2% and BMI 36.6 +/- 4.1 kg/m(2), were randomized to treatment with a single daily subcutaneous dose of 0.6 mg liraglutide (n = 21) or placebo (n = 12) for 8 weeks.
Report a problemFND-1527741706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase not statedNCT05419726

Brown Adipose Tissue Activity in Response to Semaglutide Administered to Obese Subjects.

University of California, Los Angelesn = 201 Feb 2023 to est. 1 Feb 2026

Obesity

Trial page ClinicalTrials.govUpdated 11 May 2025

CompletedPhase 2NCT01508949

Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 35Jun 2001 to Mar 2002

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 2 Nov 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.